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A simple, sensitive and specific ultra performance liquid chromatographyetandem mass
spectrometry (UPLCeMS/MS) method was developed for the analysis of isradipine in dog
plasma. After extracted with organic solvent, dog plasma samples were analyzed on an
Acquity UPLC BEH C18 column interfaced with a triple quadrupole tandem mass spec-
trometer in positive electrospray ionization mode. Acetonitrile:water:formic acid (80:20:0.3,
v/v/v) was used as the mobile phase at a flow rate of 0.2 ml/min. The chromatographic run
time of each sample was 1.4 min. The calibration curve in plasma was linear in the range of
0.1e40.0 ng/ml. The intra- and inter-day precision was within 13.5% in terms of relative
standard deviation (RSD%) and the accuracy was required to be 96.5%e98.4%. The validated
UPLCeMS/MS method was successfully applied in a pharmacokinetic study of controlled-
release isradipine in dogs.
ª 2013 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. All
rights reserved.1. Introduction suggested that isradipine has potential uses in the treatmentIsradipine [4-(4-Benzofurazanyl)-1,-4-dihydro-2,6-dimethyl-
3,5-pyridinedicarboxylic acid methyl 1-methylethyl ester
(Fig. 1)] is a dihydropyridine calcium antagonist and
commonly used to treat hypertension and angina pectoris
[1,2]. Isradipine inhibits the influx of extracellular calcium
across both the cardiac and vascular cell membranes leading




ang Pharmaceutical Univof Parkinson’s disease [4]. Isradipine is rapidly and almost
completely absorbed from the digestive tract [5]; however, it
suffers from low plasma concentrations, poor oral bioavail-
ability (17e28%) and rapid elimination due to extensive first
pass metabolism [6,7]. Controlled-release isradipine is usually
chosen in clinical treatment instead of immediate-release
isradipine to maintain longer effective concentrations and
lower incidences of side reactions.ile); fax: þ86 024 23986250.
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Fig. 1 e Structures of isradipine (A) and methyltestosterone (IS, B).
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have been developed for the analysis of isradipine in biolog-
ical fluid, including radioimmuno-assay (RIA) [5,7,8], gas
chromatography (GC) coupling with nitrogenephosphorus
detector [9] and with mass spectrometer [10,11], high-
performance liquid chromatography coupling with ultravio-
let detector (HPLCeUV) [12e14], with electrochemical detector
(HPLCeECD) [15] and with mass spectrometer (LCeMS) [16].
The reported HPLCeUV and HPLCeECD methods [12e15] with
the lower limit of quantification (LLOQ) higher than 0.5 ng/ml
were not sensitive enough for the pharmacokinetic studies of
controlled-release isradipine which showed the maximum
plasma concentrations (Cmax) at approximate 2 ng/ml [16].
Although the othermethods had an improved sensitivity, they
suffered from laborious sample preparation, interference
from metabolites or using advanced and expensive instru-
ment which was not routinely equipped in most laboratories.
Therefore, in this paper, we developed a simple, rapid and
sensitive ultra performance liquid chromatographyetandem
mass spectrometry (UPLCeMS/MS) method to analyze the
isradipine concentration in dog plasma using an API 4000
triple quadrupole tandem mass spectrometer as a detector.
The analytical method described herein was successfully
applied to the pharmacokinetic study of isradipine in Beagle
dogs after an oral dose of 5.0 mg controlled-release
isradipine.2. Materials and methods
2.1. Chemicals and materials
Isradipine (99.2% purity) and methyltestosterone (99.0% pu-
rity) were obtained from British Pharmacopoeia (Stanmore,
UK) and National Institute for the Control of Pharmaceutical
and Biological Products (Beijing, China), respectively. Isradi-
pine controlled-release tablets (Dynacirc CR) were supplied
by GlaxoSmithKline (NC, USA). HPLC-grade acetonitrile was
purchased from Dikma Technology (CA, USA). Distilled
water, prepared from demineralized water, was used
throughout the study. All other chemicals and solvents were
of analytical grade or better and used without further
purification.2.2. Instrument and UPLCeMS/MS conditions
2.2.1. Chromatographic conditions
Liquid chromatography was carried out on a Waters Acquity
series (Waters, Milford, MA). The separation was performed
on a Waters Acquity UPLC BEH C18 column (50  2.1 mm i.d.,
1.7 mm). The column temperature was kept at 30 C. The mo-
bile phase consisted of acetonitrile:water:formic acid
(80:20:0.3, v/v/v) at a flow rate of 0.2 mL/min. The injection
volume was 5 ml.
2.2.2. Mass spectrometric conditions
An API 4000 triple quadrupole tandem mass spectrometer
(Applied Biosystem/MDS SCIEX, Foster City, CA, USA) with
electrospray source (ESI) was operated in positive ion mode.
The quantification was performed using multiple reaction
monitoring (MRM) method with the transitions of m/z
372.4/ 312.2 for isradipine and m/z 303.1/ 97.2 for meth-
yltestosterone (internal standard; IS). The main working pa-
rameters were set as follows: ionspray voltage, 5.0 kV; ion
source temperature, 500 C; gas1, 50 psi; gas2, 20 psi; curtain
gas, 10 psi. Analyte concentrations were determined using the
software Analyst 1.5.2.3. Preparation of calibration standards and quality
control samples
Stock solutions of 0.5 mg/ml for isradipine and methyl-
testosterone (IS) were prepared by dissolving the requisite
amount of isradipine and IS in acetonitrile, respectively. A
series of isradipine working standard solutions with concen-
trations in the range of 1.0e400 ng/ml were obtained by
further dilution of the stock solution with acetonitrile. The
working solution of IS (400 ng/ml) was prepared in the same
way as isradipine. All solutions were stored at 20 C away
from light until analysis and they were found to be stable for
at least 25 d (data not shown).
Plasma calibration standards of isradipine at concentra-
tions of 0.10, 0.20, 1.00, 5.00, 20.00 and 40.00 ng/ml were pre-
pared as follows: a 40 ml aliquot of isradipineworking standard
solutions was spiked into an 8-ml glass tubes and the solvent
was evaporated to dryness under air stream. Blank plasma
(400 ml) was then added to each tube and the tube was
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samples of 0.20, 4.00 and 36.00 ng/ml were prepared in the
same way as calibration standards. Additional validation QCs
were prepared at 0.10 ng/ml to test LLOQ. The spiked plasma
(calibrators and QCs) was treated according to the sample
preparation described below.2.4. Sample preparation
To a 400 ml portion of each plasma sample, 40 ml of IS solution
(400 ng/ml methyltestosterone in acetonitrile) and 40 ml of
1 mol/l sodium hydroxide were added and vortex-mixed
for 10 s. After the addition of 3 ml of n-hexane:di-
chloromethane:isopropanol (2:1:0.1, v/v/v), the sample was
placed on a reciprocating shaker for 10 min at 120 rpm, fol-
lowed by centrifugation at 2110 g for 5 min. The organic layer
was separated and evaporated to dryness at 40 C under an air
stream. The residue was reconstituted in 100 ml of the mobile
phase and 5 ml was injected for UPLCeMS/MS analysis.Fig. 2 e Full-scan MS/MS spectra of [M D H]D of isradipine
(A) and methyltestosterone (IS, B).2.5. Method validation
The validation process was conducted according to Guidance
for Industrye Bioanalytical Method Validation, recommended
by FDA [17].
Specificity of the method was evaluated by analyzing six
different blank plasma samples to investigate the potential
interferences at the retention times for the analyte and IS.
The linearity of the method was assessed by processing (in
duplicate) a six-point calibration curve over the concentration
range of 0.10e40.00 ng/ml on 3 consecutive batches. Calibra-
tion curves were built by fitting the analyte concentrations of
the calibrators versus the peak area ratios of the analyte to IS
using least-squares non-linear regression analysis with a
weighting factor of 1/x2. Lower limit of quantification (LLOQ)
was defined as the lowest plasma concentration in the cali-
bration curve.
The precision and accuracy were evaluated by analyzing
QCs at plasma concentrations of 0.10 (LLOQ), 0.20, 4.00 and
36.00 ng/ml in six replicates on three separated days. The
criteria for acceptability of the data included accuracy within
100 15% of the nominal values and a precision of within 15%
relative standard deviation (RSD%) except for LLOQ at which
both precision were within 20% and accuracy were within
100  20% (US Food and Drug Administration, Center for Drug
Evaluation and Research, 2001).
The matrix effect and extraction recovery for isradipine
and IS were evaluated by assaying three groups of samples:
neat standard solutions of isradipine and IS (group 1), blank
plasma extracts from six different dogs spiked with isradipine
and IS after liquideliquid extraction (group 2), and plasma
extracts spikedwith isradipine and IS before extraction (group
3). Samples of each group were prepared at three decitabine
levels of 0.20, 4.00 and 36.00 ng/ml. The matrix effects were
calculated as the ratio of peak area of an analyte spiked post-
extraction (group 2) to its mean peak area from neat solution
(group 1). The variability (RSD) of matrix effect at each con-
centration level should be less than 15% [18]. The recoverywas
calculated as the ratio of the peak area of an analyte spikedprior to extraction (group 3) to its mean peak area after
extraction (group 2).
The stability of isradipine in dog plasma was assessed by
analyzing triplicates of QCs at 0.20 and 36.00 ng/ml, which
were exposed to different temperatures and storage condi-
tions. These QCs were analyzed after storage at room tem-
perature for 4.0 h (bench-top), at70 C for 25 days, after three
freeze-thaw cycles at 70 C and after transportation with dry
ice for 2.0 h. The stability of isradipine and IS in the injection
solvent was determined periodically by re-injecting the pro-
cessed QCs for up to 24 h (at room temperature) after the
initial injection. Samples were considered stable if assay
values were within the acceptable limits of accuracy
(100  15%) and precision (15% RSD).2.6. Pharmacokinetic study
Eight Beagle dogs (10.05  1.12 kg, half male and half female)
were supplied by Shenyang Kangping Laboratory Animal
Institute (Shenyang, China). They were housed under stan-
dard conditions and had ad libitum access to water. All
experimental procedures were performed in accordance with
the guidelines of the Experimental Animal Care and Use
Committee of Shenyang Pharmaceutical University (She-
nyang, China). After fasted for 12 h, dogs were given an oral
dose of 5.0 mg controlled-release isradipine. Blood samples
were collected into heparinized tubes before (0 h) and at 0.5,
1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 8.0, 12, 24, 36, 48 and 60 h after
administration. Plasma was separated by centrifugation at
Fig. 3 e Representative MRM chromatograms for isradipine (peak I) and methyltestosterone (IS, peak II) in dog plasma
samples. Panel A: a blank plasma sample; panel B: a blank plasma sample spiked with isradipine at the LLOQ; panel C: a dog
plasma sample collected at 12 h after drug administration.
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analysis.
The pharmacokinetic parameters of isradipine were
calculated by non-compartmental method using DAS 2.0
pharmacokinetic program (Chinese Pharmacology Society).
The maximum plasma concentrations (Cmax) and the corre-
sponding peak time (Tmax) were observed from the individual
drug plasma concentrationetime profile. The terminal elimi-
nation rate constant (ke) was estimated by log-linear regres-
sion of concentrations observed during the terminal phase of
elimination. The elimination half-life (T1/2) was calculated as
0.693/ke. The area under the plasma concentrationetime
curve was calculated by the linear trapezoidal rule.Table 2 e Summary of stability of isradipine under






(%)3. Results and discussion
3.1. Method development
Isradipine was easily ionized in the positive ionization mode
and predominantly formed an adduct ion of [M þ Na]þ at m/z
394.1 in Q1 full-scan mass spectra. The protonated molecule
ion [M þH]þ atm/z 372.4 was about 25% relative abundance of
[M þ Na]þ. However, the MRM transitions of m/z 372.4
([M þ H]þ) were more sensitive than those of m/z 394.1
([M þ Na]þ). Therefore, [M þ H]þ at m/z 372.4 was selected as
the precursor ion and the base peak atm/z 312.2 in the productTable 1 e Precision and accuracy of the UPLCeMS/MS
method to determine isradipine in dog plasma (in 3
consecutive days, six replicates for each day).
Concentration (ng/ml) Precision (RSD%) Accuracy
Added Measured Intra-day Inter-day (%)
0.10 0.10  0.01 12.0 14.1 93.5e104.7
0.20 0.20  0.02 7.7 13.2 92.3e102.7
4.00 3.89  0.38 8.7 8.2 93.5e99.7
36.00 34.70  2.6 7.6 5.0 94.3e98.0ionmass spectrum of [MþH]þ of isradipine was chosen as the
daughter ion (Fig. 2).
To improve the sensitivity of the quantification of isradi-
pine, a Waters UPLC column packed with C18 particles of
1.7 mmwas used in this method. Compared with the columns
with bigger particle size (5 mm), the peak width of isradipine
was thinner on the UPLC column and signal to noise ratio was
increased about three times. Amlodipine was used as IS in the
method reported by Park et al. [16], but it is unstable to light
like isradipine. A light-stable compound, methyltestosterone,
was used as IS in this method. Methyltestosterone showed
similar retention time and extraction recovery to isradipine.
3.2. Method validation
3.2.1. Specificity
The specificity was assessed by comparing the chromato-
grams of blank plasma samples from six different dogs with
the corresponding spiked plasma. Fig. 3 shows the typical
chromatograms of a blank plasma sample, a blank plasma
sample spiked with isradipine at the LLOQ and a dog plasmaAdded Measured
Room temperature for 4 h
(Bench-top)
0.20 0.18  0.00 1.2 11.7
36.00 32.4  3.8 11.7 9.9
Frozen (70 C) for 25 days 0.20 0.18  0.01 4.6 11.0
36.00 36.9  0.2 0.4 2.6
Three freeze-thaw cycles
at 70 C
0.20 0.17  0.01 4.8 14.5
36.00 34.5  1.9 5.5 4.1
Transportation for 2 h
(dry ice)
0.20 0.17  0.00 1.7 13.0
36.00 33.9  2.9 8.5 5.7
Post-pretreatment at room
temperature for 24 h
0.10 0.10  0.01 12.9 2.5
0.20 0.18  0.02 11.8 8.2
36.00 32.9  2.2 6.7 8.5
Fig. 4 e Mean plasma concentrationetime curve of
isradipine in 8 Beagle dogs after an oral administration of
5.0 mg controlled-release isradipine. The error bars are
standard deviations of the mean.
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controlled-release isradipine. Under the optimized chro-
matographic conditions as described in “Experimental”,
typical retention times for both isradipine and IS were 1.0min,
respectively. No significant interferences from endogenous
substances with isradipine or IS were detected.
3.2.2. Linearity and LLOQ
The plasma calibration curve was constructed using six cali-
bration standards over the concentration range of
0.10e40.00 ng/ml. A typical equation of the calibration curve
on a validation batch was as follows: y ¼ 0.0455x þ 0.000753
(r ¼ 0.9963), where y represents the peak area ratio of isradi-
pine to IS and x represents the plasma concentration of isra-
dipine. Excellent linearity was obtained in this concentration
range with a correlation coefficient (r) greater than 0.996. The
LLOQ was confirmed to be 0.1 ng/ml, at which the accuracy
was in the range of 93.5e104.7% and the precision were below
14.1% (Table 1).
3.2.3. Precision and accuracy
Table 1 summarizes the results for intra- and inter-day pre-
cision and accuracy for isradipine measured by QCs. The
intra- and inter-day precisions were all below 15% with a
maximum RSD of 13.5%, and accuracy was calculated within
96.5%e98.0%.Table 3 e Pharmacokinetic parameters of
isradipine after an oral administration of 5.0mg
controlled-release isradipine.
Parameters Mean  SD
Cmax (ng/ml) 8.47  4.54
Tmax (h) 5.0  2.2
T1/2 (h) 6.1  2.5
AUC0et (ng$h/ml) 87.4  54.5
AUC0eN (ng$h/ml) 93.2  56.33.2.4. Recovery and matrix effect
The recoveries of isradipine extracted from plasma were
83.3  4.5, 88.0  7.7 and 83.2  4.2% at the concentrations of
0.20, 4.00 and 36.00 ng/ml, respectively (n ¼ 6). The recovery of
IS at 40 ng/ml was 80.1 3.1%. Thematrix effects of isradipine
from six different dog plasma samples at concentrations of
0.20, 4.00 and 36.00 ng/mlwere in the range of 86.5e89.7%with
RSD values below 8.5%. The matrix effect of IS (40 ng/ml in
plasma) was 98.3% and the RSD value was 3.8%. These results
indicated that the effect of matrix on the determination of
isradipine could be ignored.
3.2.5. Stability
Table 2 contains the results of investigations into the stability
of isradipine under the various conditions tested throughout
the validation process. The tests were designed to cover
anticipated conditions which might be encountered during
sample handling and processing. The results indicated the
stability of isradipine in plasma after storage at room tem-
perature for 4.0 h (bench-top), at70 C for 25 days, after three
freeze-thaw cycles at 70 C, during transportation for 2.0 h
(dry ice) and in processed samples at room temperature for
24 h.
3.3. Pharmacokinetic study
The validated LCeMS/MS method was successfully applied to
the pharmacokinetic study of isradipine in Beagle dogs after
an oral administration of 5.0 mg controlled-release isradipine.
The assay was found to be sufficiently sensitive and specific
for the accurate determination of isradipine in dog plasma
samples. The mean plasma concentrationetime curve of
isradipine is shown in Fig. 4 and the main pharmacokinetic
parameters of isradipine are presented in Table 3. As observed
in human [16], marked individual difference was also found in
the pharmacokinetic profile of isradipine in Beagle dogs after
drug administration. The peak concentrations of isradipine
were arrived from 2 till 8 h. The values of T1/2 of isradipine
varied from 3.2 to 10.3 h. High variability in Cmax and AUC
made their RSD values higher than 50%.4. Conclusion
A simple, rapid and sensitive UPLCeMS/MS method has been
developed and validated for the analysis of isradipine in dog
plasma. This method showed high throughput (1.4 min each
sample) and good sensitivity with an LLOQ of 0.10 ng/ml. This
method was successfully applied to characterize the phar-
macokinetics of controlled-release isradipine in Beagle dogs.r e f e r e n c e s
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